Calcifediol vitamin D supplement tested in adults with pulmonary arterial hypertension
Tests a calcifediol vitamin D supplement against placebo in adults with pulmonary arterial hypertension.
Key facts
- Who runs it
- Consorci Mar Parc De Salut De Barcelona
- Where
- Barcelona, Las Palmas De Gran Canaria, Madrid, Santander, Sevilla, and Valencia, SpainSee the 10 sites
- Trial code
- Registry title
- REstoration with calcifediol of VItamin D deficiency in pulmonary Arterial Hypertension patients (REVIDAH study)
- Status
- Not yet recruiting
- Phase
- Phase 4
- People taking part
- 102 people, planned
- Started
- 2 Jun 2025
- Expected to end
- 30 Nov 2027
- Type of study
- Interventional
- Record updated
- 20 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 75 with certain types of pulmonary arterial hypertension (PAH) and a severe vitamin D deficiency, who are stable on their usual PAH treatment.
- Age
- 18 to 75 years
- Sex
- Men and women
- Disease stage
- PAH of these types: idiopathic, hereditary, drug- and toxin-induced, or linked to a connective tissue disease. Risk score intermediate-low or intermediate-high (2022 ERS/ESC guidelines).
- Earlier treatment
- Stable on standard PAH medicines (alone or combined) or on a stable dose of diuretics, with no change for at least 6 weeks before randomization. No current vitamin D supplements, bisphosphonates, calcitonin, parathormone or mitramicine.
- Biomarker or test result
- Severe vitamin D deficiency: plasma or serum 25(OH)vitD level of 12 ng/ml or lower.
Main reasons for not taking part
- Other types of pulmonary hypertension, or serious lung disease
- Osteoporosis, osteomalacia or other calcium or phosphorus problems
- Pregnant or breastfeeding women, or women who could become pregnant and do not use effective contraception
- Serious heart problems, such as uncontrolled high blood pressure or permanent atrial fibrillation
- Clinically relevant liver problems, kidney insufficiency, or active treatment with digoxin
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Male and female patients aged 18 -75 years
- Patients with diagnosis of PAH of the following types according to 2022 ERS/ESC guidelines: idiopathic, hereditary, drug- and toxin-induced PAH or associated to connective tissues disease
- Patients who are stable and treated with standard medications for PAH on monotherapy or with combinations of drugs, including calcium channel blockers, phosphodiesterase type 5 inhibitors (PDE5i), endothelin receptor antagonists (ERA), prostacyclin analogues or selexipag or with stable dose of diuretics who had no treatment modification for at least 6 weeks before randomization
- Patients with an intermediate-low and intermediate-high risk score according to 2022 ERS/ESC guidelines
- Patients with severe deficiency of vitD, defined herein as plasma or serum 25(OH)vitD levels equal to or lower than 12 ng/ml
- Patients who can understand and follow instructions, and who are able to participate in the study for the entire study
- Patients must have given their written informed consent to participate in the study after having received adequate previous information and before any study-specific procedures
Who cannot take part
- Participation in another interventional clinical study within 30 days before screening
- Exclusion criterion related to hypoxia (pulse oximeter at rest): Peripheral capillary oxygen saturation <88% despite supplemental oxygen therapy (≤4 L/min) at rest
- Cardiovascular exclusion criteria: a. Uncontrolled arterial hypertension (systolic blood pressure (SBP) >180 mm Hg and/or diastolic BP (DBP) >110 mm Hg). b. SBP <95 mm Hg before and at randomisation. c. Resting heart rate in the awake patient <50 bpm or >105 bpm. d. Permanent atrial fibrillation and new onset of atrial fibrillation within the 3 months before screening. e. Left ventricular systolic dysfunction by echocardiography (<40%, Simpson's methodology). f. Hypertrophic obstructive cardiomyopathy. g. Severe proven or suspected coronary artery disease. h. Clinical evidence of symptomatic atherosclerotic disease. i. History of stroke within 3 months before and at randomisation. j. Congenital or acquired valvular or myocardial disease if clinically significant apart from tricuspid valvular insufficiency due to PAH. k. Three or more of the following left ventricular disease/dysfunction risk factors: i. Body mass index≥30 kg/m2, ii. History of essential hypertension, iii. Diabetes mellitus of any type, iv. History of significant coronary disease
- Active treatment with vitD supplements, bisphosphonates, calcitonin, parathormone or mitramicine
- Previous randomization to treatment during this study (no re-randomization)
- Patients with substance abuse (eg, alcohol or drug abuse) within the previous 3 months before and at randomisation
- Patients with a history of severe allergies or multiple drug allergies or with hypersensitivity to the investigational drug or any of the excipients
- Excluded medication/treatment: active treatment with digoxin
- Patients with a medical disorder, condition, or history of such that would impair the patient's ability to participate in or complete this study, in the opinion of the investigator
- Patients unable to perform a valid 6MWD test (eg, orthopaedic disease or peripheral artery occlusive disease that affects the patient's ability to walk)
- Previous diagnosis of osteoporosis, osteomalacia or other alterations of calcium or phosphorus homeostasis
- Patients with underlying medical disorders with an anticipated life expectancy <2 years
- Pregnant women or breastfeeding women, or women with childbearing potential not using an effective contraception method throughout the study
Where in Spain
- Hospital Clinic BarcelonaBarcelona, SpainNot yet recruiting
- Hospital del MarBarcelona, SpainNot yet recruiting
- Hospital Vall d'HebronBarcelona, SpainNot yet recruiting
- El Hospital Universitario De Gran Canaria Dr. NegrinLas Palmas De Gran Canaria, SpainNot yet recruiting
- Ramón y Cajal University HospitalMadrid, SpainNot yet recruiting
- Hospital Universitario Marqués de ValdecillaSantander, SpainNot yet recruiting
- Hospital Virgen del RocioSevilla, SpainNot yet recruiting
- Consorcio Hospital General Universitario de ValenciaValencia, SpainNot yet recruiting
- Hospital La FeValencia, SpainNot yet recruiting
- Hospital Universitario Doctor PesetValencia, SpainNot yet recruiting
About the trial
What the trial wants to find out
To analyze whether a vitamin D supplement (0,266 mg calcifediol, once every ten days for the first 12 weeks and once every two weeks in the following 12 weeks) induces clinical improvement without clinical worsening at week 24 compared with placebo. Clinical improvement is defined as a change in at least two of the following variables: 1) increase in 6 minutes walking distance (6MWD) >= 10% or more than 30 m, 2) change from intermediate-2 low or intermediate-high risk to low risk score or change from intermediate-high to intermediatelow risk according to 2022 ERS/ESC guidelines), 3) reduction in BNP or NT-proBNP >= 30%, 4) increase in the TAPSE/SPAP ratio >=25%.Clinical worsening is defined as any of the following events: a) hospitalization related to PAH, b) therapeutic escalation, c) progression of symptoms, d) lung or cardiopulmonary transplantation, e) atrial septostomy and f) mortality related to PAH.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- REstoration with calcifediol of VItamin D deficiency in pulmonary Arterial Hypertension patients (REVIDAH study)
- Plain-language title
- Calcifediol vitamin D supplement tested in adults with pulmonary arterial hypertensionGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 20 March 2026